2. Academic Validation
  3. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications

EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications

  • Oncogene. 2015 Oct 8;34(41):5277-87. doi: 10.1038/onc.2014.448.
S A Greenall 1 2 3,  J F Donoghue 1 2,  M Van Sinderen 1 2,  V Dubljevic 1 2,  S Budiman 1 2,  M Devlin 4,  I Street 5 6 7,  T E Adams 3,  T G Johns 1 2
Affiliations

Affiliations

  • 1 Oncogenic Signalling Laboratory and Brain Cancer Discovery Collaborative, Centre for Cancer Research, MIMR-PHI Institute of Medical Research, Clayton, VIC, Australia.
  • 2 Monash University, Clayton, VIC, Australia.
  • 3 Division of Materials Science and Engineering, Commonwealth Scientific and Industrial Research Organisation, Parkville, VIC, Australia.
  • 4 Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, VIC, Australia.
  • 5 CRC for Cancer Therapeutics, Bundoora, VIC, Australia.
  • 6 The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • 7 Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
PMID: 25659577 DOI: 10.1038/onc.2014.448
Abstract

A truncation mutant of the epidermal growth factor receptor, EGFRvIII, is commonly expressed in glioma, an incurable brain Cancer. EGFRvIII is tumorigenic, in part, through its transactivation of other Receptor Tyrosine Kinases (RTKs). Preventing the effects of this transactivation could form part of an effective therapy for glioma; however, the mechanism by which the transactivation occurs is unknown. Focusing on the RTK MET, we show that MET transactivation in U87MG human glioma cells in vitro is proportional to EGFRvIII activity and involves MET heterodimerization associated with a focal adhesion kinase (FAK) scaffold. The transactivation of certain other RTKs was, however, independent of FAK. Simultaneously targeting EGFRvIII (with panitumumab) and the transactivated RTKs themselves (with motesanib) in an intracranial mouse model of glioma resulted in significantly greater survival than with either agent alone, indicating that cotargeting these RTKs has potent antitumor efficacy and providing a strategy for treating EGFRvIII-expressing gliomas, which are usually refractory to treatment.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z